The Oncology Institute, Inc. provides value-based community oncology care through clinics and affiliate locations across multiple states. Company updates commonly cover quarterly results, payor and Medicare Advantage contract activity, capitated care models, specialty pharmacy performance, clinical trials, transfusions, and participation in CMS oncology care programs.
News also addresses clinical pathways, legal and compliance leadership, and healthcare investor conference participation. The issuer's public securities include common stock under TOI and redeemable warrants under TOIIW.
The Oncology Institute (NASDAQ: TOI) reported Q1 2026 results for the quarter ended March 31, 2026. Consolidated revenue was $147.4 million, up 41.2% year-over-year; gross profit was $23.3 million, up 35.2%.
Q1 net loss narrowed to $2.5 million from $19.6 million; adjusted EBITDA improved to $(2.4) million. Specialty pharmacy revenue rose 78% and the company expects 200,000 Medicare Advantage lives in Florida effective July 1, 2026. 2026 guidance largely unchanged; free cash flow range updated to $5–$15 million.
The Oncology Institute (NASDAQ: TOI) will release first quarter 2026 financial results on Thursday, May 7, 2026, followed by a conference call the same day at 5:30 p.m. ET. A live dial-in, international numbers, and a simultaneous webcast via the Investor Relations website are provided.
A replay will be available two hours after the call through Thursday, May 21, 2026 using the provided replay numbers and passcode 11161701.
The Oncology Institute (NASDAQ: TOI) achieved $1.8 million in Medicare savings during CMS Enhancing Oncology Model Performance Period 3, equal to more than $6,400 per patient episode. This improves on Performance Period 2 savings of $1.1 million ($3,500+ per episode).
TOI earned maximum quality scores on avoidable emergency department visits and hospital admissions for a second consecutive period, driven by its High-Value Cancer Care program, care navigation, Health Care Coach symptom monitoring, and 24/7 symptom management.
The Oncology Institute (NASDAQ: TOI) announced that CEO Dr. Daniel Virnich and CFO Rob Carter will participate in the 25th Annual Needham Healthcare Conference on Wednesday, April 15, 2026, including a fireside chat at 3:45 p.m. ET.
A live webcast of the presentation will be accessible via the company's Investor Relations website.
The Oncology Institute (NASDAQ: TOI) appointed Minh Merchant as Chief Legal Officer effective April 6, 2026. Ms. Merchant will oversee legal, regulatory, compliance and privacy functions to support TOI's scaling as a national oncology platform.
She brings more than two decades of healthcare legal experience, prior general counsel roles at Midi Health, Kyverna Therapeutics, Aspira Women’s Health and McKesson, and a JD from UCLA School of Law.
The Oncology Institute (NASDAQ: TOI) reported Q4 2025 revenue of $142.0M (+41.6%) and full-year 2025 revenue of $502.7M (+27.8%), with gross profit of $76.4M for 2025 (+41.6%).
Q4 adjusted EBITDA was $0.15M, full-year adjusted EBITDA was $(12.4)M, net loss for 2025 was $(60.6)M, and cash totaled $33.6M as of Dec 31, 2025. 2026 guidance: revenue $630–650M, gross profit $97–107M, adjusted EBITDA $0–9M, free cash flow $(15)–5M.
The company expects ~$150M in capitated revenue in 2026 and anticipates Q1 2026 adjusted EBITDA of $(1)M to $(3)M due to seasonality and reimbursement timing.
The Oncology Institute (NASDAQ: TOI) will release fourth quarter and full year 2025 financial results on Thursday, March 12, 2026, followed by a conference call the same day at 5:00 p.m. ET. Investors can join via phone or webcast.
A replay will be available two hours after the call through Thursday, March 19, 2026 using the provided passcode; international dial-in and webcast details are available on the investor relations site.
The Oncology Institute (NASDAQ: TOI) announced executive participation in three investor conferences in March 2026. Presentations include Jefferies Healthcare Services Innovation & Technology Summit and Leerink Global Healthcare Conference on March 9 in Miami, and Oppenheimer MedTech & Services Conference (virtual) on March 16.
Presenters include Dr. Daniel Virnich, CEO, and Rob Carter, CFO; webcasts and replays will be available via the company Investor Relations site.
The Oncology Institute (NASDAQ: TOI) appointed Kim Tzoumakas to its Board of Directors, effective February 23, 2026.
Ms. Tzoumakas brings more than two decades of executive leadership in oncology, pharmacy services and healthcare operations, currently serving as CEO of VytlOne National Pharmacy Services and with prior CEO and board experience.
The Oncology Institute (NASDAQ: TOI) reaffirmed 2025 guidance and provided a preliminary 2026 outlook on Jan 12, 2026. For 2026 the company expects total revenue of $630 million to $650 million, ~28% growth from the 2025 midpoint, including about $150 million of Capitation revenue.
TOI forecasts Adjusted EBITDA of $0 million to $9 million for 2026 (midpoint would be its first full year of Adjusted EBITDA profitability as a public company) and says profitability from newly onboarded delegated contracts will build through 2026 with fuller economics in 2027.
Longer term, TOI targets ~20% annual revenue growth through 2028, expects Capitation and Dispensary to be ~30% and 50% of revenue respectively, and projects margins expanding to the mid-single-digit range by 2028.